Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 131

1.

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.

Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, Huang JJ, Ashby CR Jr, Chen ZS.

Drug Resist Updat. 2019 Nov 11;48:100663. doi: 10.1016/j.drup.2019.100663. [Epub ahead of print]

PMID:
31785545
2.

Advanced technological tools to study multidrug resistance in cancer.

Andrei L, Kasas S, Ochoa Garrido I, Stanković T, Suárez Korsnes M, Vaclavikova R, Assaraf YG, Pešić M.

Drug Resist Updat. 2019 Oct 17;48:100658. doi: 10.1016/j.drup.2019.100658. [Epub ahead of print]

PMID:
31678863
3.

The multi-factorial nature of clinical multidrug resistance in cancer.

Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH.

Drug Resist Updat. 2019 Sep;46:100645. doi: 10.1016/j.drup.2019.100645. Epub 2019 Sep 17.

PMID:
31585396
4.

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.

Leonetti A, Wever B, Mazzaschi G, Assaraf YG, Rolfo C, Quaini F, Tiseo M, Giovannetti E.

Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.

PMID:
31585395
5.

Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo.

Engelberg S, Netzer E, Assaraf YG, Livney YD.

Cell Death Dis. 2019 Sep 20;10(10):702. doi: 10.1038/s41419-019-1870-0.

6.

Metabolomics reveals novel insight on dormancy of aquatic invertebrate encysted embryos.

Rozema E, Kierszniowska S, Almog-Gabai O, Wilson EG, Choi YH, Verpoorte R, Hamo R, Chalifa-Caspi V, Assaraf YG, Lubzens E.

Sci Rep. 2019 Jun 20;9(1):8878. doi: 10.1038/s41598-019-45061-x.

7.

Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.

Levin M, Stark M, Berman B, Assaraf YG.

Cell Death Dis. 2019 May 17;10(6):390. doi: 10.1038/s41419-019-1626-x.

8.

Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer.

Edelman R, Assaraf YG, Slavkin A, Dolev T, Shahar T, Livney YD.

Pharmaceutics. 2019 May 5;11(5). pii: E216. doi: 10.3390/pharmaceutics11050216.

9.

Correction: Demonstrating aspects of multiscale modeling by studying the permeation pathway of the human ZnT2 zinc transporter.

Golan Y, Alhadeff R, Glaser F, Ganoth A, Warshel A, Assaraf YG.

PLoS Comput Biol. 2019 May 1;15(5):e1007021. doi: 10.1371/journal.pcbi.1007021. eCollection 2019 May.

10.

ZnT2 is an electroneutral proton-coupled vesicular antiporter displaying an apparent stoichiometry of two protons per zinc ion.

Golan Y, Alhadeff R, Warshel A, Assaraf YG.

PLoS Comput Biol. 2019 Mar 20;15(3):e1006882. doi: 10.1371/journal.pcbi.1006882. eCollection 2019 Mar.

11.

Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity.

Zhitomirsky B, Yunaev A, Kreiserman R, Kaplan A, Stark M, Assaraf YG.

Cell Death Dis. 2018 Dec 13;9(12):1191. doi: 10.1038/s41419-018-1227-0.

12.

MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.

Leonetti A, Assaraf YG, Veltsista PD, El Hassouni B, Tiseo M, Giovannetti E.

Drug Resist Updat. 2019 Jan;42:1-11. doi: 10.1016/j.drup.2018.11.002. Epub 2018 Nov 28. Review.

PMID:
30544036
13.

Modulating ROS to overcome multidrug resistance in cancer.

Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, Ashby CR Jr, Yang DH, Chen ZS.

Drug Resist Updat. 2018 Nov;41:1-25. doi: 10.1016/j.drup.2018.11.001. Epub 2018 Nov 14. Review.

PMID:
30471641
14.

High proportion of transient neonatal zinc deficiency causing alleles in the general population.

Golan Y, Lehvy A, Horev G, Assaraf YG.

J Cell Mol Med. 2019 Feb;23(2):828-840. doi: 10.1111/jcmm.13982. Epub 2018 Nov 18.

15.

Demonstrating aspects of multiscale modeling by studying the permeation pathway of the human ZnT2 zinc transporter.

Golan Y, Alhadeff R, Glaser F, Ganoth A, Warshel A, Assaraf YG.

PLoS Comput Biol. 2018 Nov 2;14(11):e1006503. doi: 10.1371/journal.pcbi.1006503. eCollection 2018 Nov. Erratum in: PLoS Comput Biol. 2019 May 1;15(5):e1007021.

16.

β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.

Bar-Zeev M, Kelmansky D, Assaraf YG, Livney YD.

Eur J Pharm Biopharm. 2018 Dec;133:240-249. doi: 10.1016/j.ejpb.2018.10.018. Epub 2018 Oct 24.

PMID:
30367935
17.

Cancer cell-selective, clathrin-mediated endocytosis of aptamer decorated nanoparticles.

Engelberg S, Modrejewski J, Walter JG, Livney YD, Assaraf YG.

Oncotarget. 2018 Apr 20;9(30):20993-21006. doi: 10.18632/oncotarget.24772. eCollection 2018 Apr 20.

18.

The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity.

Levin M, Stark M, Assaraf YG.

Oncotarget. 2018 Mar 30;9(24):16861-16882. doi: 10.18632/oncotarget.24717. eCollection 2018 Mar 30.

19.

Redundant angiogenic signaling and tumor drug resistance.

Gacche RN, Assaraf YG.

Drug Resist Updat. 2018 Jan;36:47-76. doi: 10.1016/j.drup.2018.01.002. Epub 2018 Jan 17. Review.

PMID:
29499837
20.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.

Supplemental Content

Loading ...
Support Center